Navigation: Home > Terms of use Welcome to our site!

Terms of Use

The DRAR-CPI Server ("the Website" or "the Server") is owned and operated by Bio-X Institutes. Your access to the Website is subject to these terms of use and disclaimers of specific parts of the Website ("Terms of Use"). We may at our sole discretion modify, remove, add, change, or amend, any part of these conditions of use and to delete, change, or amend any features of the website or services available through this website without notice or liability.

According to Nucleic Acids Research Web Server Issue policy,

  1. This website is free and open to all users and there is no login requirement.
  2. In case the server does not return the results immediately, a link to the results will be provided, through which the user can bookmark and access at a later time to view job status. The server will send an email to the user when the job is done. However, providing the email address is optional.
  3. User's submission and the results are private and are not shown to others.

Accuracy of Information

The developing team does not warrant that the information contained in, or accessible through this website is accurate, complete, without error, or suitable for your intended use. Subject to any terms implied by law and which cannot be excluded, the developing team does not accept any liability for any costs, claims, expenses, charges, losses, damages or penalties of any kind incurred directly or indirectly (including indirect, special or consequential loss or damage) through your use of the DRAR-CPI server or your reliance on the information on or available through the website or any error, omission or misrepresentation in any information on the website or available through the DRAR-CPI server.

Privacy Policy

We Respect your Privacy.
The DRAR-CPI Developing Team respects your privacy and works hard to safeguard the security of your account and personal information.

Personal Information: What is it?
Personal information is any information such as your name, address, or telephone number that may identify you, or by which your identity can be reasonably determined.

How we collect your Information?
We will only collect information relevant to our research relationship with you. The information we collect from you may include contact details and personal details. This is done solely for the aim and purpose of best meeting your particular needs.

Your Personal Information is never sold to Third Parties.
We do not sell any personally-identifiable information or lists or any other information collected by applications, telephone communications, fax, mail, e-mail or online on our web sites for random purposes.

Security
We use up to date techniques to ensure your information is secure, including encryption, firewalls and other technology and security procedures to help protect the accuracy and security of your personal information and prevent unauthorized access or improper use.

Disclaimer

The DRAR-CPI Developing Team and Bio-X Institutes ("We") exclude all liability for any costs, claims, expenses, charges, losses, damages or penalties of any kind incurred directly or indirectly (including indirect, special or consequential loss or damage) arising from the use of, or reliance on, any information on the website or available through the website whether or not caused by any negligent act or omission.

By using our server, you will be assuming all risks associated with use of the site, including risk to your computer, software, or data being damaged by any virus which might be transmitted or activated via the website or your access to it. By using our server, you will have deemed to have released and discharged us from all liability which might arise.

We have not reviewed any of the websites which link to this website or to which this website links. We are not responsible for the content of any other websites or pages linked to or linking to this website. We do not endorse or otherwise sponsor such links. Such links are provided solely for your convenience and information. Following links to any other websites or pages shall be at your own risk.

DRAR-CPI SOFTWARE USAGE AGREEMENT

THIS SOFTWARE LICENSE AGREEMENT ("Agreement") is made by and between The Bio-X Institutes at Shanghai Jiao Tong University (BIOX), having an address at 1954 Huashan Road, Shanghai, China, 200030 and_____________________, having an address at______________________("Recipient") and__________________________________________________ (Recipient Scientist).

This Agreement is for registered users only.

RECITALS

A. BIOX is the owner of the Software (as defined below).

B. BIOX desires to grant to Recipient and Recipient desires to obtain from BIOX a non-exclusive license to use the DRAR-CPI Software solely in accordance with the terms and on the conditions set forth in this Agreement.

NOW, THEREFORE, the parties hereto agree as follows:

1. DEFINITIONS.

1.1 "Software" shall mean the DRAR-CPI computer program in on-line web server form.

2. GRANT OF RIGHTS. The License granted for Software under this Agreement authorizes Recipient on a nonexclusive basis to use the Software through the on-line server. Recipient agrees to use the Software for either non-commercial or commercial purpose for free.

3 . MODIFICATIONS.

3 .1 Other Modifications. Recipient may, from time to time, request that BIOX incorporate certain features, enhancements or modifications into the Software. BIOX may, in its sole discretion, undertake to incorporate such changes, which shall be the sole property of BIOX, and distribute the Software so modified to all or any of BIOX's licensees. Any modifications or derivative works based on the Software are considered part of the Software and ownership thereof is retained by BIOX.

4 . PROTECTION OF LICENSED SOFTWARE.

4 .1 Proprietary Notices. Recipient agrees to respect and not to remove, obliterate, or cancel from view any copyright, trademark, confidentiality or other proprietary notice, mark, or legend appearing on any of the Software or output generated by the Software, and to reproduce and include same on each copy of the Software. A citation of our published article will be appropriate (see below).

4 .2 Protection of Ownership. Recipient agrees to use its best efforts, consistent with the practices and procedures Recipient takes to protect Recipients own most valuable proprietary information and materials, and will take all reasonable steps to protect the Software and any pertinent documentation and associated trade secrets against any unauthorized use, reproduction, disclosure or distribution.

4 .3 Research Publications, including scientific papers, films, videotapes and CDs, by the Recipient Scientist resulting from the use of the Software should properly cite the following publications:

Heng Luo, Jian Chen, Leming Shi, Mike Mikailov, Huang Zhu, Kejian Wang, Lin He* and Lun Yang* . DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome. Nucl. Acids Res. (2011)doi: 10.1093/nar/gkr299

Lun Yang*, Kejian Wang, Jian Chen, Anil G Jegga, Heng Luo, Leming Shi, Chunling Wan, Xizhi Guo, Shengying Qin, Guang He, Guoyin Feng, Lin He*. Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study. PLoS Computational Biology. 2011;7(3):e10002016. doi:10.1371/journal.pcbi.1002016

Lun Yang*, Jian Chen, Leming Shi, Michael P Hudock, Kejian Wang, Lin He*. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One. 2010;5(3):e9568. doi:10.1371/journal.pone.0009568

Lun Yang*, Jian Chen, Lin He*. Harvesting Candidate Genes for Serious Adverse Drug Reactions from a Chemical-Protein Interactome. PLoS Computational Biology. 2009;5(7):e1000441. doi:10.1371/journal.pcbi.1000441

Lun Yang*, Heng Luo, Jian Chen, Qinghe Xing, Lin He*. SePreSA, a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Research. 2009;37(Web Server issue):W406-12. doi:10.1093/nar/gkp312. service available at http://sepresa.bio-x.cn/

A short citation should at least include the first reference.

5 . CONFIDENTIALITY.

5 .1 Acknowledgement. Recipient hereby acknowledges and agrees that the Software constitutes and contains valuable proprietary products and trade secrets of BIOX embodying substantial creative efforts and confidential information, ideas, and expressions. Accordingly, Recipient agrees to treat (and take precautions to ensure that its employees treat) the Software as confidential, not to disclose or permit to any third party or entity access to the Software or any portion thereof without the written permission of a duly authorized representative of BIOX.

5 .2 Injunctive Relief. Recipient acknowledges that the unauthorized use, transfer or disclosure of the Software or copies thereof will (i) substantially diminish the value to BIOX of the trade secrets and other proprietary interests that are the subject of this Agreement; (ii) render BIOX's remedy at law for such unauthorized use, disclosure or transfer inadequate; and (iii) cause irreparable injury in a short period of time. If Recipient breaches any of its obligations with respect to the use or confidentiality of the Software, BIOX shall be entitled to seek equitable relief to protect its interests therein, including, but not limited to, preliminary and permanent injunctive relief.

5 .3 Survival. Recipient's obligations under this Article 7 will survive the termination of this Agreement or of any license granted under this Agreement for whatever reason.

6 . WARRANTIES; SUPERIOR RIGHTS.

6 .1 Government Rights. Recipient understands that the Software may have been developed under a funding agreement with the Government of the People’s Republic of China and, if so, that the Government may have certain rights relative thereto. This Agreement is explicitly made subject to the Government's rights under any such agreement and any applicable law or regulation, if any. To the extent that there is a conflict between any such agreement, applicable law or regulation and this Agreement, the terms of such Government agreement, applicable law or regulation shall prevail.

6 .2 Disclaimer of Warranties. ANY INFORMATION, MATERIALS OR SERVICES FURNISHED BY BIOX PURSUANT TO THIS AGREEMENT ARE ON AN AS IS BASIS. BIOX DOES NOT REPRESENT OR WARRANT THAT ALL ERRORS IN THE SOFTWARE WILL BE CORRECTED. THERE ARE NO WARRANTIES RESPECTING THE SOFTWARE OR SERVICES PROVIDED HEREUNDER, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, EVEN IF BIOX HAS BEEN INFORMED OF SUCH PURPOSE OR THAT THE SOFTWARE WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. NO AGENT OF BIOX IS AUTHORIZED TO ALTER OR EXCEED THE WARRANTY OBLIGATIONS OF BIOX AS SET FORTH HEREIN.

7 . INDEMNIFICATION.

Except to the extent prohibited by law, Recipient shall indemnify and hold harmless, BIOX, its trustees, officers, agents and employees from and against any claims, demands, or causes of action whatsoever, including without limitation those arising on account of Recipient's modification or enhancement of the Software or otherwise caused by, or arising out of, or resulting from, the exercise or practice of the license granted hereunder by Recipient, its sublicensees, if any, its subsidiaries or their officers, employees, agents or representatives.

8 . NONASSIGNABILITY. Any and all assignments of this Agreement or any rights granted hereunder by Recipient without the prior written consent of BIOX are void except (i) to an affiliate of Recipient or (ii) as expressly permitted hereunder.

9 . GOVERNING LAW; JURISDICTION AND VENUE. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the People’s Republic of China.

1 0 . SEVERABILITY. If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and effect.

This Agreement and its exhibits contain the entire understanding and agreement between the parties respecting the subject matter hereof. This Agreement may not be supplemented, modified, amended, released or discharged except by an instrument in writing signed by each party's duly authorized representative. All captions and headings in this Agreement are for purposes of convenience only and shall not affect the construction or interpretation of any of its provisions. Any waiver by either party of any default or breach hereunder shall not constitute a waiver of any provision of this Agreement or of any subsequent default or breach of the same or a different kind. IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Agreement as of the date first set forth above.